Aenova Holding GmbH

  • High-volume OSDF manufacturing Aenova Tittmoning
  • Aenova Development Services
  • Aenova CDMO Site Marburg
  • Aenova High potent drug products Feldkirchen site
  • Aenova QC Laboratory Sisseln site
About Aenova Holding GmbH

The Aenova Group is a leading global contract manufacturer and development service provider for the pharmaceutical and healthcare industries. As a full-service provider, Aenova develops, produces and packages all common dosage forms, product groups and active ingredient classes of pharmaceuticals and food supplements for human and animal health: solid, semi-solid and liquid, sterile and non-sterile, high and low dose, OEB 1-5, and fill&finish of biologics/vaccines up to BSL-2. Around 4,200 employees at 14 locations worldwide contribute to Aenova's success.
Aenova is expanding its development and production portfolio, particularly in the area of bioavailability of active pharmaceutical ingredients and with differentiated technologies for complex therapeutic systems, e.g. intelligently encapsulated mini tablet systems or multi-unit pellet systems (MUPS), hot melt extrusion, dry powder inhaler (DPI) platform for micro-dosed capsule filling, co-precipitation, particle sizing and lipid-based soft capsule formulations. 

  • DE
  • 2015
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Contract Service
Contact info
Meet us at

CPHI Milan 2024

Fiera Milano, Italy
08 Oct 2024 - 10 Oct 2024

Products from Aenova Holding GmbH (7)

  • Diclofenac / Omeprazole, HGC, modified release

    Product Diclofenac / Omeprazole, HGC, modified release

    Pharmaceutical Licensing Product
    Chemical for symptomatic treatment of RA, osteoarthritis, ankylosing spondylitis

    Aenova offers a broad range of pharmaceutical license products under the following license model:
    • Aenova provides and updates dossiers and scientific materia...
  • Propiverine Hydrochloride, FCT

    Product Propiverine Hydrochloride, FCT

    Pharmaceutical Licensing Product
    Chemical for urinary incontinence

    Aenova offers a broad range of pharmaceutical license products under the following license model:
    • Aenova provides and updates dossiers and scientific material  •  Licensee prepares dossier ...
  • Ethinylestradiol / Levonorgestrel, SCT

    Product Ethinylestradiol / Levonorgestrel, SCT

    Pharmaceutical Licensing Product
    Chemical for oral contraception (2nd generation)

    Aenova offers a broad range of pharmaceutical license products under the following license model:
    • Aenova provides and updates dossiers and scientific material  •  Licensee prepar...
  • Diclofenac Dual Release, HGC

    Product Diclofenac Dual Release, HGC

    Pharmaceutical Licensing Product
    Chemical for pain and inflammation

    Aenova offers a broad range of pharmaceutical license products under the following license model:
    • Aenova provides and updates dossiers and scientific material  •  Licensee prepares dossier...
  • Horse Chestnut Seeds Extract, HGC, Cream or Ointment

    Product Horse Chestnut Seeds Extract, HGC, Cream or Ointment

    Pharmaceutical Licensing Product
    Herbal for venous insufficiency

    Aenova offers a broad range of pharmaceutical license products under the following license model:
    • Aenova provides and updates dossiers and scientific material  •  Licensee prepares dossier ac...
  • Metformin Hydrochloride, FCT

    Product Metformin Hydrochloride, FCT

    Pharmaceutical Licensing Product
    Chemical for diabetes type II

    Aenova offers a broad range of pharmaceutical license products under the following license model: 
    • Aenova provides and updates dossiers and scientific material    • Licensee prepares dos...
  • Vegapure(R) Emulsorb, SGC

    Product Vegapure(R) Emulsorb, SGC

    Consumer Health Care Product Concept Cholesterol control Aenova offers broad expertise in the development of Consumer Health Care products: Thorough understanding of global and regional market needs Creation of new product concepts based on current and foreseen innovation trends Strong support to ensure...

Aenova Holding GmbH Resources (10)

  • News Aenova opens new building for the production of highly potent drugs

    Aenova opened its new building for highly potent active ingredients at the Regensburg site on June 22, 2023. Highly potent drugs against cancer, among other things, are produced in the new production facilities. With a total investment of around 25 million euros at the Regensburg site, Aenova will thus be able to significantly increase its development and production capacities for the increased market demand for highly effective drugs.
  • News Innovative drug formulations make medicines more patient-friendly: Aenova and Galvita enter strategic partnership

    The Aenova Group is a leading global contract manufacturer and development service provider for the pharmaceutical and healthcare industry. As a full service provider, Aenova develops, produces and packages all common dosage forms, product groups and active ingredient classes from pharmaceuticals to dietary supplements for human and animal health. Galvita is an innovative Swiss start-up company specializing in the development of patient-friendly, age-appropriate dosage forms.
  • Brochure AENOVA CAPABILITIES

    As a leading global contract manufacturer and development service providerwith 15 production sites in Europe and the USA, we offer extensive capabilitiesfor Steriles, Semi-Solids, Solids and Packaging.
  • News Aenova white paper on "Development of highly potent medicines”

    HPAPIs (highly potent active pharmaceutical ingredients), provide precision treatment for cancer, autoimmune disorders, infectious diseases, and other medical conditions. Their safe handling is a challenge for drug manufacturers, who have to meet equipment, environmental and product quality requirements in the production and development of HPAPIs.
  • Brochure AENOVA IP GmbH

    Aenova offers a broad range of license products.
  • News Aenova publishes white paper on the "Safe and efficient handling of high potent drug products"

    High-potent drug products for oncology or hormone therapy will play an important role in innovative drug therapy in the future. The development and production of drugs with high-potent active ingredients is highly complex and often must be implemented with acceleration. Handling of high potent solid dosage forms therefore is a key need of current pharmaceutical development and manufacturing. To ensure safe and efficient handling of high potency products, mastering a holistic production approach is essential. This drives a fast time-to-market for your new high potent product. 
     
  • Brochure Softgels

    Unique ProductionKnow-How MaximizesMarket Potential
  • News Aenova expands portfolio with innovative technologies

    The development of new drug products for a wide range of therapeutic areas is a rapidly growing market. Therefore, a smart innovation strategy is essential for contract developers and manufacturers. Aenova is expanding its development and production portfolio, particularly in the area of bioavailability of active pharmaceutical ingredients.

  • Brochure VegaGels Chewable Capsules

    Softgel capsules are starting to be widely used not only for pharmaceuticals and food supplements but also for cosmetics, fragrances, general processed foods, and the like.